Biosafety considerations associated with molecular farming in genetically modified plants

Journal of Medicinal Plants Research

Volumn 3, Issue 11, 2009, Pages 825-838

  Breyer, Didier ^a   Goossens, Martine ^a   Herman, Philippe ^a   Sneyers, Myriam ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Biopharming; Biosafety; Confinement; Containment; Genetically modified organism; Plant molecular farming; Plant made industrials; Plant made pharmaceuticals

Indexed keywords

RECOMBINANT PROTEIN;

BIOSAFETY; CONTAMINATION; CULTIVATED SPECIES; DRUG SYNTHESIS; FOOD CHAIN; GENETIC ENGINEERING; NONHUMAN; PLANT BIOTECHNOLOGY; PLANT MOLECULAR FARMING; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; TECHNIQUE; TRANSGENE; TRANSGENIC PLANT;

EID: 73649127285     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Becker G, Vogt D (2005). Regulation of Plant-Based Pharmaceuticals. CRS Report for Congress. Order Code RS21418, March 8.
2. Daniell H, Streatfield SJ, Wycoff K. (2001a). Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 6: 219-226.
3. Daniell H, Khan MS, Allison L (2001b). Milestones in chloroplast genetic engineering: an environmental friendly era in biotechnology. Trends Plant Sci. 7: 84-91.
4. Daniell H, Lee SB, Panchal T, Wiebe PO (2001c). Expression and assembly of the native cholera toxin B subunit gene as functional oligo-mers in transgenic tobacco chloroplasts. J. Mol. Biol. 311: 1001-1009.
5. Daniell H (2002). Molecular strategies for gene containment in transgenic corps. Nat. Biotechnol. 20: 581-586.
6. Daniell H (2006). Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. Biotechnol. J. 1(10): 1071-1079.
7. De Cosa B, Moar W, Lee SB, Miller M, Daniell H (2001). Over-expression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat. Biotechnol. 19: 71-74.
8. Decker EL, Reski R (2007). Moss bioreactors producing improved biophar-maceuticals. Curr. Opin. Biotechnol. 18: 393-398.
9. Dunwell JM, Ford CS (2005). Technologies for biological containment of GM and non-GM crops. Defra contract CPEC 47. Final report. http://www.gmo-safety. eu/pdf/biosafenet/Defra-2005.pdf [accessed 25 August 2009].
10. Eastham K, Sweet J (2002). Genetically Modified Organisms (GMOs): The Significance of Gene Flow Through Pollen Transfer. Environmental Issue Report 28 (European Environment Agency, Copenhagen, Denmark).
11. EC (2001). Council Directive 2001/18/EC of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official J. Eur. Union L106:1-38.
12. EC (2002). Commission Decision 2002/623/EC of 24 July establishing guidance notes supplementing Annex II to Directive 2001/18/EC of the European Parliament and of the Council on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official J. Eur. Union L200: 22-33.
13. EC (2003). Regulation (EC) No 1829/2003 of 22 September on genetically modified food. Official Journal of the European Union L268: 1-23.
14. EC (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official J. Eur. Union L136:1-33.
15. EC (2009). Directive 2009/41/EC of the European Parliament and of the Council of 6 May on the contained use of genetically modified microorganisms. Official J. Eur. Union L125: 75-97.
16. EFSA (2006). Guidance document of the scientific panel on genetically modified organisms for the risk assessment of genetically modified plants and derived food and feed. EFSA J. 99: 1-100.
17. EFSA (2009). Scientific Opinion on Guidance for the risk assessment of genetically modified plants used for non-food or non-feed purposes. EFSA-Q-2007-176. EFSA J. 1164: 1-42.
18. EMEA (2008). Guidelines on the quality of biological active substances produced by stable transgene expression in higher plants. EMEA/CHMP/BWP/48316/ 2006.
19. Elbehri A (2005). Biopharming and the Food System: Examining the Potential Benefits and Risks. Ag. Biol. Forum 8(1): 18-25.
20. Ellstrand NC (2003). Going to 'great lengths' to prevent the escape of genes that produce specialty chemicals. Plant Physiol. 132: 1770-1774.
21. FDA (2002). Draft Guidance for Industry. Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm124811.pdf [accessed 25 August 2009].
22. Federal Register Notice (2003). 68 FR 11337-11340. http://www.aphis.usda. gov/brs/pdf/7cfr.pdf [accessed 25 August 2009].
23. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM (2004). Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 7: 152-158.
24. Floss DM, Falkenburg D, Conrad U (2007). Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: An overview. Transgenic Res. 16: 315-332.
25. Fox JL (2003). Puzzling industry response to prodigene fiasco. Nat. Biotechnol. 21: 3-4.
26. Franklin SE, Mayfield SP (2005). Recent developments in the production of human therapeutic proteins in eukaryotic algae. Expert Opin. Biol. Ther. 5: 1225-235.
27. Freese B (2002). Manufacturing Drugs and Chemicals in Crops. Biopharming poses new threats to consumers, farmers, food companies and the environment. Genetically Engineered Food Alert. http://www.kahea.org/gmo/pdf/FOE-biopharm- exsumm.pdf [25 August 2009].
28. Gils M, Kandzia R, Marillonnet S, Klimyuk V, Gleba Y (2005). High-yield production of authentic human growth hormone using a plant virus-based expression system. Plant Biotechnol. J. 3:613-20.
29. Goldstein DA, Thomas JA (2004). Biopharmaceuticals Derived from Genetically Modified Plants. QJM: Int. J. Med. 97: 705-716.
30. Gomord V, Chamberlain P, Jefferis R, Faye L (2005). Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23:559-65.
31. Graff G, Moschini G (2004). Pharmaceuticals and industrial products in crops: economic prospects and impact on agriculture. Iowa Ag. Rev. 10: 4-11.
32. Grevich JJ, Daniell H (2005). Chloroplast genetic engineering: Recent advances and future perspectives. Crit. Rev. Plant Sci. 24: 83-107.
33. Hagemann R (2004). The sexual inheritance of plant organelles. In: Mole-cular Biology and Biotechnology of Plant Organelles. Daniell H, Chase C (Ed.). Springer Publishers, Dordrecht, Netherlands pp. 93-113.
34. Harl NE, Ginder RG, Hurgurgh CR, Moline S (2003). The Starlink™ Situation. Ames, IA: Iowa State University Extension. http://www.biotech-info. net/0010star.PDF [accessed 25 August 2009].
35. Hellwig S, Drossard J, Twyman RM, Fischer R (2004). Plant cell cultures for the production of recombinant proteins. Nat. Biotechnol. 22:1415-1422.
36. Hennegan K, Yang DC, Nguyen D, Wu LY, Goding J, Huang JM, Guo FL, Huang N, Watkins S (2005). Improvement of human lysozyme expression in transgenic rice grain by combining wheat (Triticum aestivum) puroindoline b and rice (Oryza sativa) Gt1 promoters and signal peptides. Transgenic Res. 14: 583-592.
37. Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, Flynn P, Register J, Marshall L, Bond D (1997). Commercial production of avidin from transgenic maize: characterization of transformant, pro-duction, processing, extraction and purification. Mol. Breed. 3: 291-306.
38. Hood EE (2002). From green plants to industrial enzymes. Enzyme Microbial Technol. 30: 279-283.
39. Howard JA (2005). Commercialization of Biopharmaceutical and Bioindustrial Proteins from Plants. Crop Sci. 45: 468-472.
40. Howard JA, Hood EE (2007). Methods for growing nonfood products in transgenic plants. Crop Sci. 47:1255-1262.
41. Jones PBC (2003). Cultivating Ground Rules for Biopharming. ISB News Report. http://www.isb.vt.edu/news/2003/news03.jun.html [accessed 25 August 2009].
42. Kirk DD, McIntosh K, Walmsley AM, Peterson RK (2005). Risk analysis for plant-made vaccines. Transgenic Res. 14: 449-162.
43. Kumar GBS, Ganapathi TR, Bapat VA (2007). Production of Hepatitis B Surface Antigen in Recombinant Plant Systems: An Update. Biotechnol. Progress 23: 532 - 539.
44. Liénard D, Sourrouille C, Gomord V, Faye L. (2007). Pharming and transgenic plants. Biotechnol Annu Rev. 13: 115-47.
45. Lee D, Natesan E (2006) Evaluating genetic containment strategies for transgenic plants. Trends Biotechnol. 24: 109-114.
46. Lu BR (2003). Transgene containment by molecular means - is it possible and cost effective? Environ. Biosafety Res. 2: 3-8.
47. Ma JK, Drak PM, Christou P (2003). The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 4: 794-805.
48. Ma JK, Barros E, Bock R, Christou P, Dale PJ, Dix PJ, Fischer R, Irwin J, Mahoney R, Pezzotti M, Schillberg S, Sparrow P, Stoger E, Twyman RM (2005a). Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep. 6: 593-599.
49. Ma JK, Chikwamba R, Sparrow P, Fischer R, Mahoney R, Twyman RM (2005b). Plant-derived pharmaceuticals - the road forward. Trends Plant Sci. 10: 580-585.
50. Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba, Y (2005). Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat. Biotechnol. 23: 718-723.
51. Mascia PN, Flavell RB (2004). Safe and acceptable strategies for producing foreign molecules in plants. Curr. Opin. Plant Biol. 7: 189-195.
52. Molina A, Hervas-Stubbs S, Daniell H, Mingo-Castel AM, Veramendi J (2004). High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts. Plant Biotechnol. J. 2: 141-153.
53. Moschini G (2006). Pharmaceutical and Industrial Traits in Genetically Modified Crops: Co-existence with Conventional Agriculture. Working Paper 06-WP 429. Center for Agricultural and Rural Development.
54. Murphy DJ (2007). Improving containment strategies in biopharming. Plant Biotechnol. J. 5: 555-569.
55. NARA (2005). Introductions of plants genetically engineered to produce industrial compounds. Federal register (USA), 70 (85):23009-23011.
56. NRC (2004). Biological Confinement of Genetically Engineered Organisms. The National Academies Press, Washington DC, USA, ISBN 0-309-09085-7.
57. Oliver MJ, Quisenberry JE, Trolinder NLG, Keim DL (1998). Control of plant gene expression. US patent 5,723,765.
58. Peterson RKD, Arntzen CJ (2004). On risk and plant-based biopharmaceuticals. Trends Biotechnol. 22:64-66.
59. Pizzuti F, Daroda L (2008). Investigating recombinant protein exudation from roots of transgenic tobacco. Environ. Biosafety Res. 7: 219-26.
60. Plasson C, Michel R, Lienard D, Saint-Jore-Dupas C, Sourrouille C, de March GG, Gomord V (2009). Production of recombinant proteins in suspension-cultured plant cells. Methods Mol. Biol. 483: 145-161.
61. Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, Brinker A, Moreno DA, Ripoll C, Yakoby N, O'Neal JM, Cornwell T, Pastor I, Fridlender B (2002). Plants and human health in the twenty-first century. Trends Biotechnol. 20: 522-531.
62. Ruf S, Karcher D, Bock R (2007). Determining the transgene containment level provided by chloroplast transformation. Proc. Natl. Acad. Sci. USA, 104(17): 6998-7002.
63. Ruiz ON, Daniell H (2005). Engineering cytoplasmic male sterility via the chloroplast genome by the expression of beta-ketothiolase. Plant Physiol. 138: 1232-1246.
64. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 5: 579-90.
65. Sparrow PA, Irwin JA, Dale PJ, Twyman RM, Ma JK (2007). Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res. 16(2): 147-61.
66. Sparrow PA, Twyman RM (2009). Biosafety, Risk Assessment and Regu-lation of Plant-made Pharmaceuticals. Methods Mol. Biol. 483:341-53.
67. Spök A (2007). Molecular farming on the rise - GMO regulators still walking a tightrope. Trends Biotechnol. 25: 74-82.
68. Spök A, Karner S (2008). Plant Molecular Farming, Opportunities and Challenges. JRC Technical Report EUR 23383 EN. Luxembourg: Office for Official Publications of the European Communities.
69. Spök A, Twyman RM, Fischer R, Ma JKC, Sparrow PAC (2008). Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol. 646:1-12.
70. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L, Ward D, Ye G, Russell DA (2000). High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat. Biotechnol. 18: 333-338.
71. Stoger E, Ma JK, Fischer R, Christou P (2005). Sowing the seeds of success: pharmaceutical proteins from plants. Curr. Opin. Biotechnol. 16(2): 167-73.
72. Streatfield SJ, Howard JA (2003). Plant-based vaccines. Int. J. Parasitol. 33: 479-493.
73. Streatfield SJ, Lane JR, Brooks CA, Barker DK, Poage ML, Mayor JM, Lamphear BJ, Drees CF, Jilka JM, Hood EE, Howard JA (2003). Corn as a production system for human and animal vaccines. Vaccine. 21: 812-815.
74. Svab Z, Maliga P (2007). Exceptional transmission of plastids and mitochondria from the transplastomic pollen parent and its impact on transgene containment. Proc. Natl. Acad .Sci. U S A. 104: 7003-7008.
75. Tackaberry ES, Prior F, Bell M, Tocchi M, Porter S, Mehic J, Ganz PR, Sardana R, Altosaar I, Dudani A (2003). Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome 46: 521-526.
76. Twyman R, Stoger E, Schillberg S, Christou P, Fischer R (2003). Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 21: 570-578.
77. Twyman RM, Schillberg S, Fischer R (2005). The transgenic plant market in the pharmaceutical industry. Expert Opin. Emerg. Drugs 10: 185-218.
78. Union of Concerned Scientists (2006). UCS Position Paper: Pharmaceutical and Industrial Crops. UCS. http://www.ucsusa.org/food-and-environment/genetic- engineering/ucs-position-paper.html [accessed 25 August 2009].
79. USDA (2002). Pharming the field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals. Proceedings from a workshop sponsored by the Pew Initiative on Food and Biotechnology, the U.S. Food and Drug Administration and the Cooperative State Research, Education and Extension Service of the U.S. Department of Agriculture.
80. USDA (2006a). Permitting genetically engineered plants that produce pharmaceutical compounds. BRS Factsheet.http://www.aphis.usda.gov/publications/ biotechnology/content/printable-version/BRS-FS-pharmaceutical-02-06.pdf [accessed 25 August 2009].
81. USDA (2008). Guidance for APHIS Permits for Field Testing or Movement of Organisms Intended for Pharmaceutical or Industrial Use. http://www.aphis.usda. gov/brs/pdf/Pharma-Guidance.pdf [accessed on 25 August 2009].
82. Vancanneyt G, Dubald M, Schröder W, Peters J, Botterman J (2009). A case study for plant-made pharmaceuticals comparing different plant expression and production systems. Methods Mol. Biol. 483: 209-221.
83. Verma D, Daniell H (2007). Chloroplast vector systems for biotechnology applications. Plant Physiol. 145: 1129-1143.
84. Vézina LP, Faye L, Lerouge P, D'Aoust MA, Marquet-Blouin E, Burel C, Lavoie PO, Bardor M, Gomord V (2009). Transient co-expression for fast and high-yield production of antibodies with human-like Nglycans in plants. Plant Biotechnol. J. 7: 442-455.
85. Vitale A, Pedrazzini E (2005). Recombinant pharmaceuticals from plants: The plant endomembrane system as bioreactor. Mol. Interven. 5: 216-225.
86. Walker TL, Purton S, Becker DK, Collet C (2005). Microalgae as bioreactors. Plant Cell Rep 24: 629-641.
87. Wang T, Li Y, Shi Y, Reboud X, Darmency H, Gressel J (2004). Low frequency transmission of a plastid-encoded trait in Setaria italica. Theor. Appl. Genet. 108: 315-320.
88. Witcher DR (1998). Commercial production of b-glucuronidase (GUS): a model system for the production of proteins in plants. Mol. Breed. 4: 301-312.
89. Wolt JD, Karaman S, Wang K (2007). Risk assessment for plant-made pharmaceuticals. CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutr. Nat. Resour. 2(12): 1-9.
90. Woodard SL, Mayor JM, Bailey MR, Barker DK, Love RT, Lane JR, Delaney DE, McComas-Wagner JM, Mallubhotla HD, Hood EE, Dangott LJ, Tichy SE, Howard JA (2003). Maize (Zea mays)-derived bovine trypsin: characterization of the first large-scale, commercial product from transgenic plants. Biotechnol. Appl. Biochem. 38: 123-130.
91. Wycoff KL (2005). Secretory IgA antibodies from plants. Curr. Pharm. Des. 11: 2429-37.
92. Zavon JA, Flinn JE. (2003). Future of pharming involves look at big picture. Feedstuffs 75(25): A11.